Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus

Abstract

To determine the outcome and identify risk factors for evolution into systemic lupus erythematosus (SLE) in a population of incomplete lupus erythematosus (ILE) patients, we studied the clinical and serologic manifestations in a cohort of 87 ILE patients. ILE patients had at least one but less than four of the American College of Rheumatology (ACR) classification criteria of SLE and did not present distinctive clinical features or meet classification criteria of other connective tissue diseases. The patients that remained with ILE were compared with patients that evolved into SLE and with a cohort of 94 SLE patients. The mean disease duration and follow up of ILE patients were 4.44.1 and 2.2 2.4 years respectively. Eight patients evolved into SLE, but none presented major organ damage. At baseline, patients that remained with ILE were less likely to have photosensitivity, elevated anti-dsDNA and decreased C3 complement than patients that evolved into SLE. At the end of the study, malar rash and oral ulcerations were also less frequent in the ILE group. Compared with all SLE cases, ILE patients were less likely to have photosensitivity, malar rash, oral ulcers, Raynaud's phenomenon, arthritis, low C3, low C4, positive anti-dsDNA, anti-Sm, anti-RNP, anti-Ro and anti-La antibodies at baseline. Hazard analyses showed that malar rash, oral ulcers, elevated anti-dsDNA and decreased C4 were associated with SLE occurrence. In conclusion, this study suggests that ILE represents a mild spectrum of lupus in which mucocutaneous and serological abnormalities are associated with progression into SLE. Lupus (2000) 9, 110±115

Keywords

systemic lupus erythematosus incomplete lupus erythematosus latent lupus clinical outcome risk factors

Get full access to this article

View all access options for this article.

References

Mukerji B , Hardin JG . Undifferentiated, overlapping, and mixed connective tissue diseases . Am J Med Sci 1993; 305: 114–119 .

Alarcón GS , Willkens RF , Ward JR et al. Early undifferentiated connective tissue disease. IV. Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline . Arthritis Rheum 1996; 39: 403–414 .

Williams HJ , Alarcón GS , Neuner R et al. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: diseaseremissions and changes in diagnoses in well established and undifferentiated connective tissue diseases . J Rheumatol 1998; 25: 261–268 .

Danieli MG , Fraticelli P , Salvi A , Gabrielli A , Danieli G . Undifferentiatedconnective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD . Clin Rheumatol 1998; 17: 195–201 .

Mosca M , Tavoni A , Neri R , Bencivelli W , Bombardieri S . Undifferentiated connective tissue diseases: the clinical and serological profiles of91 patients followed for at least 1 year . Lupus 1998; 7: 95–10 .

Greer JM , Panush RS . Incomplete lupus erythematosus . Arch Intern Med 1989; 149: 2473–2476 .

Ganczarczyk L , Urowitz MB , Gladman DD . “Latent Lupus” . J Rheumatol 1989; 16: 475–478 .

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

Arnett FC , Edworthy SM , Bloch DA et al. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis . Arthritis Rheum 1988; 31: 315–324 .

10.

Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee . Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Arthritis Rheum 1980; 23: 581–590 .

11.

Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts) . N Engl J Med 1975; 292: 344–347 .

12.

Vitali C , Bombardieri S , Moutsopoulus HM et al. Preliminary criteria for the classification of Sjögren's syndrome . Arthritis Rheum 1993; 36: 340–347 .

13.

Hunder GG , Bloch DA , Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis . Arthritis Rheum 1990; 33: 1122–1128 .

14.

Arend WP , Michel BA , Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis . Arthritis Rheum 1990; 33: 1129–1134 .

15.

Lightfoot RW Jr , Michel BA , Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa . Arthritis Rheum 1990; 33: 1088–1093 .

16.

Leavitt RY , Fauci AS , Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis . Arthritis Rheum 1990; 33: 1101–1107 .

17.

Masi AT , Hunder GG , Lie JT et al. The American College of Rheumatology 1990criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis) . Arthritis Rheum 1990; 33: 1094–1100 .

18.

Mills JA , Michel BA , Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura . Arthritis Rheum 1990; 33: 1114–1121 .

19.

Calabrese LH , Michel BA , Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis . Arthritis Rheum 1990; 33: 1108–1113 .

20.

International Study Group for Behçet's Disease . Criteria for diagnosis of Behçet's disease . Lancet 1990; 335: 1078–1080 .

21.

Alarcón-Segovia D , Pérez-Vázquez ME , Villa AR , Drenkard C , Cabiedes J . Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus . Semin Arthritis Rheum 1992; 21: 275–286 .

22.

Dougados M , Van Der Linden S , Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy . Arthritis Rheum 1991; 34: 1218–1227 .

23.

Wolfe F , Smythe HA , Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia . Report of the multicenter criteria committee. Arthritis Rheum 1990; 33: 160–172 .

24.

Cervera R , Khamashta MA , Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients . Medicine 1993; 72: 113–124 .

25.

Crosstabs . In: SPSS Base 8.0 User's Guide. SPSS Inc: Chicago , 1998, pp 201–206.

26.

Jeckel J , Elmore J , Katz D . Statistical Inference and Hypothesis Testing. In: Epidemiology Biostatistics and Preventive Medicine . WB Saunders Company: Philadelphia , 1996, 128–135.

27.

Jeckel J , Elmore J , Katz D . TheKaplan–Meier Method. In: Epidemiology Biostatistics and Preventive Medicine . WB Saunders Company: Philadelphia , 1996, 155–158.

28.

Armitage P . Berry G . Survival Analysis . In: Statistical Methods in Medical Research. Blackwell Scientific Publications: Oxford , 1988, pp 421–439.

29.

Calvo-Alén J , Bastian HM , Straaton KV et al. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center . Arthritis Rheum 1995; 38: 1475–1484

30.

Wallace DJ , Schwartz E , Chi-Lin H , Peter JB . The `rule out lupus' rheumatology consultation: clinical outcomes and perspectives . J Clin Rheumatol 1995; 1: 158–164 .

31.

Calvo–Alén, J , Alarcón GS , Burgard SL et al. Systemic lupus erythematosus: predictors of its occurrence among acohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors . J Rheumatol 1996: 23: 469–475 .

32.

Vilá LM, Mayor AM , Valentín AH , García-Soberal M , VilaÁ S . Clinical and immunological manifestations in 134 Puerto Rican patients with systemic lupus erythematosus . Lupus 1999; 8; 279–286 .

33.

Nossent JC , Swaak AJ . Systemic lupus erythematosus VII: frequency and impact of secondary Sjögren's syndrome . Lupus 1998; 7: 231–234 .

34.

Gladman DD , Urowitz MB , Gough J , MacKinnon A . Fibromyalgia is a major contributor to quality of life in lupus . J Rheumatol 1997; 24: 2145–2148 .